FDA Grants Priority Review to Aducanumab, Biogen’s New Alzheimer’s Treatment
MEDICATION TRIALS: The FDA has accepted Biogen’s application for aducanumab, an investigational treatment for Alzheimer’s, and even granted it Priority Review, with an action date